| 1 |
国家药品监督管理局药品评审中心. 药物临床试验适应性设计指导原则(试行)[EB/OL]. (2021-01-29) [2024-12-10]. https://www.cde.org.cn/ zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129.
|
| 2 |
Chen YH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising[J]. Stat Med, 2004, 23 (7): 1023- 1038.
doi: 10.1002/sim.1688
|
| 3 |
Denne JS. Sample size recalculation using conditional power[J]. Stat Med, 2001, 20 (17/18): 2645- 2660.
doi: 10.1007/978-3-030-49528-2_28
|
| 4 |
Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials[J]. J Biopharmac Stat, 2008, 18 (6): 1184- 1196.
doi: 10.1080/10543400802369053
|
| 5 |
Mehta C, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples[J]. Stat Med, 2011, 30 (28): 3267- 3284.
doi: 10.1002/sim.4102
|
| 6 |
Lachin JM. A review of methods for futility stopping based on conditional power[J]. Stat Med, 2005, 24 (18): 2747- 2764.
doi: 10.1002/sim.2151
|
| 7 |
Pong A, Chow SC. Handbook of adaptive designs in pharmaceutical and clinical development [M]. Boca Raton, Florida: CRC Press, 2011: 94-110.
|
| 8 |
Glimm E. Comments on ‘Adaptive increase in sample size when interim results are promising: a practical guide with examples’[J]. Stat Med, 2012, 31 (1): 98- 99.
doi: 10.1002/sim.4424
|
| 9 |
Zhu J, Li X, Liu Y. An optimal hybrid approach to calculate conditional power[J]. Stat Biopharmac Res, 2022, 14 (4): 480- 492.
doi: 10.1080/19466315.2022.2063171
|
| 10 |
Jennison C, Turnbull BW. Adaptive sample size modification in clinical trials: start small then ask for more ?[J]. Stat Med, 2015, 34 (29): 3793- 3810.
doi: 10.1002/sim.6575
|
| 11 |
Proschan MA, Lan G, Wittes JT. Statistical monitoring of clinical trials: a unified approach [M]. New York: Springer Science Business Media, 2006: 43-60.
|
| 12 |
Lan KK, Wittes J. The B-value: a tool for monitoring data[J]. Biometrics, 1988, 44 (2): 579- 585.
|
| 13 |
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials[J]. Biometrics, 1999, 55 (3): 853- 857.
doi: 10.1111/j.0006-341X.1999.00853.x
|
| 14 |
Wang P, Chow SC. Sample size re-estimation in clinical trials[J]. Stat Med, 2021, 40 (27): 6133- 6149.
doi: 10.1002/sim.9175
|
| 15 |
Liu GF, Zhu GR, Cui L. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval[J]. Stat Med, 2008, 27 (4): 584- 596.
doi: 10.1002/sim.2998
|
| 16 |
Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic‐valve replacement [J]. New Engl J Med, 387(2022): 1253-1263.
|
| 17 |
Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without Thrombectomy[J]. N Engl J Med, 2024, 391, 203- 212.
doi: 10.1056/NEJMoa2402980
|
| 18 |
Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial[J]. JAMA, 2024, 331 (12): 1015- 1024.
doi: 10.1001/jama.2024.1361
|